

1 **A Multi-Center Randomized, Double-Blind, Placebo Controlled,**  
2 **Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and**  
3 **Tolerability of an Anthocyanin Rich Extract (ACRE) in Patients with**  
4 **Ulcerative Colitis**

5 **Luc Biedermann<sup>1†</sup>, Michael Doulberis<sup>1,2,3†</sup>, Philipp Schreiner<sup>1</sup>, Ole**  
6 **Haagen Nielsen<sup>4</sup>, Frans Olivier The<sup>1</sup>, Stephan Brand<sup>5</sup>, Sabine Burk<sup>1</sup>,**  
7 **Petr Hruz<sup>6</sup>, Pascal Juillerat<sup>7</sup>, Claudia Krieger – Grübel<sup>5</sup>, Kristin Leu<sup>1</sup>,**  
8 **Gabriel Leventhal<sup>1</sup>, Benjamin Misselwitz<sup>7</sup>, Sylvie Scharl<sup>1</sup>, Alain**  
9 **Schoepfer<sup>8</sup>, Frank Seibold<sup>9</sup>, Hans Herfarth<sup>10\*</sup>, Gerhard Rogler<sup>1\*□</sup>**

---

10 <sup>1</sup>Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich,  
11 8091 Zurich, Switzerland [luc.biedermann@usz.ch](mailto:luc.biedermann@usz.ch), [philippschreiner@hotmail.com](mailto:philippschreiner@hotmail.com), [sabine.burk@usz.ch](mailto:sabine.burk@usz.ch)  
12 [gabriel@leventhal.ch](mailto:gabriel@leventhal.ch), [Sylvie.Scharl@usz.ch](mailto:Sylvie.Scharl@usz.ch), [Gerhard.rogler@usz.ch](mailto:Gerhard.rogler@usz.ch),  
13 [fransolivier.the@triemli.zuerich.ch](mailto:fransolivier.the@triemli.zuerich.ch), [leu.kristin@gmail.com](mailto:leu.kristin@gmail.com)

14 <sup>2</sup>Gastroklinik, Private Gastroenterological Practice, Horgen, Switzerland. [doulberis@gmail.com](mailto:doulberis@gmail.com)

15 <sup>3</sup>Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau,  
16 Aarau, Switzerland.

17 <sup>4</sup>Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, 2730  
18 Herlev, Denmark [ole.haagen.nielsen@regionh.dk](mailto:ole.haagen.nielsen@regionh.dk)

19 <sup>5</sup>Department of Gastroenterology and Hepatology, Kantonsspital St. Gallen, 9007 St. Gallen,  
20 Switzerland [stephan.brand@kssg.ch](mailto:stephan.brand@kssg.ch), [Claudia.Krieger-Gruebel@kssg.ch](mailto:Claudia.Krieger-Gruebel@kssg.ch)

21 <sup>6</sup>Department of Gastroenterology, Clarunis - University Center for Gastrointestinal and Liver  
22 Diseases, 4052 Basel, Switzerland [petr.hruz@clarunis.ch](mailto:petr.hruz@clarunis.ch)

23 <sup>7</sup>Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of  
24 Bern, 3010 Bern, Switzerland [pascal.juillerat@insel.ch](mailto:pascal.juillerat@insel.ch), [benjamin.misselwitz@insel.ch](mailto:benjamin.misselwitz@insel.ch)

25 <sup>8</sup>Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and  
26 University of Lausanne, 1011 Lausanne, Switzerland [alain.schoepfer@chuv.ch](mailto:alain.schoepfer@chuv.ch)

27 <sup>9</sup>Cabinet de Gastroentérologie, Balsiger, Seibold & Partenaires, Villars-sur-Glâne, 1752 Fribourg,  
28 Switzerland [frank.seibold@magendarmsuisse.ch](mailto:frank.seibold@magendarmsuisse.ch)

29 <sup>10</sup>University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, NC  
30 27514 Chapel Hill, NC, USA [hans\\_herfarth@med.unc.edu](mailto:hans_herfarth@med.unc.edu)

31 † Sharing equally first position

32 \* Sharing equally last position

33

34 **Short title:** ACRE for active refractory ulcerative colitis

35

36 □ **Corresponding author:** Prof. Gerhard Rogler MD, PhD, Chief and Chairman of  
37 Department of Gastroenterology and Hepatology, University Hospital Zurich, Raemistrasse  
38 100, 8091 Zurich, Switzerland. Phone +41 44 255 24 01. E-mail: [Gerhard.rogler@usz.ch](mailto:Gerhard.rogler@usz.ch)

39

40 **Funding:** This work was supported by grants from the Swiss National Science Foundation  
41 (SNF) to GR [Grant No. 33IC30\_166844] and the Litwin Foundation (New Hyde Park, NY).

42 **Clinicaltrials.gov number:** NCT04000139

43 **Ethical approval number:** BASEC2017-00156

44 **Informed consent statement:** All patients signed an informed consent form

45 **Data availability statement:** Data available on request due to privacy/ethical restrictions

46 **Conflicts of interest:**

47 PS received consulting fees from Pfizer, Abbvie, Takeda and Janssen-Cilag and travel  
48 support from Falk, UCB and Pfizer.

49 LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap,  
50 Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma.

51 GR declares consulting fees from Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene,  
52 FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche,  
53 UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; speaker's honoraria from Astra  
54 Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller;  
55 and grants support from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD,  
56 Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller.

57 BM reports traveling fees from Takeda, Vifor, Gilead and MSD. BM received fees as a  
58 speaker from Takeda. BM has served at an advisory board for Gilead, Takeda and BMS. BM  
59 has received research grants from MSD and BMS unrelated to the submitted work.

60 MD reports traveling fees from Takeda, FALK, Abbvie as well as consulting fees from  
61 Takeda.

62 Rest of the authors declare no compelling conflict of interests.

63

64 **Abstract**

65 **Background:** In an open label pilot study dried bilberries were effective in inducing

66 clinical, endoscopic and biochemical improvement in ulcerative colitis (UC) patients.

67 Aim was the investigation of efficacy of anthocyanin rich extract (ACRE), the

68 presumptive active ingredient of bilberries, in a controlled clinical trial in moderate-

69 severe UC.

70 **Methods:** We performed a multicenter randomized, placebo-controlled, double-blind

71 study (planned initially for 100 patients; premature termination due to COVID-19

72 pandemic). Patients had moderate-severe active UC at screening (Mayo-score 6-12,

73 endoscopic sub-score at least 2) and were randomized at baseline (verum: placebo,

74 2:1). Continuation of all UC-directed stable medical therapy was allowed. Primary

75 endpoint was clinical response at week 8 (reduction of total Mayo-score at least 3

76 points). Biochemical (fecal calprotectin) and centrally-read endoscopic response were

77 amongst the secondary endpoints.

78 **Results:** Out of 48 patients screened in six Swiss trial centers, 34 were randomized.

79 Eighteen ACRE and eight placebo patients could be analyzed in the Per-Protocol-Set.

80 Half (9/18) of ACRE patients and 3/8 of placebo patients revealed clinical response at

81 week 8 (CI 0.399-6.963; p=0.278). An improvement of the Mayo-score was observed in

82 77.8% of ACRE treated patients (62.5% of placebo). Fecal calprotectin dropped from

83 1049+/-1139 to 557+/-756µg/g feces in the ACRE but not in the placebo group (947+/-

84 1039 to 1040+/-1179; p=0.035). Adverse events were rare.

85 **Conclusions:** ACRE therapy was not significantly superior to placebo at inducing a  
86 clinical response. However, placebo response was unusual high. Moreover, there  
87 was a significant calprotectin decrease at end of treatment, indicative of ACRE  
88 biochemical efficacy in UC.

89

90 Clinicaltrials.gov number: NCT04000139

91 Word count: 250

92 **Keywords:** Ulcerative colitis, anthocyanin rich extract (ACRE), inflammatory bowel  
93 disease (IBD), complementary therapy, bilberries

## 94 **Study Highlights**

95

96 What is known:

97 • Dried bilberries have been reported to ameliorate active ulcerative colitis (UC)

98 in an uncontrolled pilot trial

99 • Anthocyanins (flavonoids) are regarded to be the active anti-inflammatory

100 compound of bilberries

101 • An anthocyanin rich extract (ACRE) of bilberries was reported to ameliorate

102 colitis in mouse models

103

104 What is new here:

105 • In a multi-center randomized, double-blind, placebo controlled, parallel group

106 study in patients with moderate to severe active UC, ACRE did not reach the

107 statistical endpoint of clinical response

108 • An unusually high placebo response was observed

109 • ACRE induced significant biochemical response with significant decrease in

110 calprotectin levels

111 **Abbreviations**

112 5-ASA, aminosalicylic acid (mesalazine); AC, anthocyanins; ACRE, anthocyanin rich  
113 extract; CI, confidence interval; IBD, inflammatory bowel disease; IFN, interferon; IL,  
114 interleukin; NF- $\kappa$ B, nuclear factor kappa B; NSAID, non-steroidal anti-inflammatory  
115 drugs; OR, odds ratio; PPS, Per-Protocol-Set; ROS, reactive oxygen species; PRO,  
116 patient reported outcome; QOL, quality of life; SIBDQ, short inflammatory bowel  
117 disease questionnaire; TNF, tumor necrosis factor; TMS, total Mayo score; UC,  
118 ulcerative colitis

119

120 Word count (introduction to conclusion): 3377

121

122 **Introduction**

123 Ulcerative colitis (UC) comprises along with Crohn's disease, the most common  
124 forms of inflammatory bowel diseases (IBD). UC is an idiopathic, chronic relapsing  
125 pathology of the colon affecting mainly young adults with a peak age range between  
126 30 - 40 years and no gender predominance. Amongst the most typical symptoms are  
127 severe, often bloody diarrhea, as well as abdominal discomfort. Although the clinical  
128 course is variable, most patients suffer from recurrent flares and an unpredictable  
129 disease course.<sup>1,2</sup> Quality of life may be severely impaired by persistent, frequent,  
130 recurrent or waxing and waning symptoms.<sup>3</sup>

131 Despite the incurable nature of the disease, about two thirds of all UC patients  
132 with moderate disease activity can be successfully treated with mesalamine (5-

133 ASA).<sup>4,5</sup> Nevertheless, patients who do not achieve a sufficient response remain a  
134 clinical challenge and up to 10% of all patients have to undergo colectomy in the  
135 long-term, according to a very recent (2023) systematic review and meta-analysis.<sup>6</sup>

136 Although there is a plethora of potential effective drugs to treat UC, the overall  
137 profile of those is far from being ideal: They harbor a considerable risk of short- and  
138 long-term toxicity and numerous side effects.<sup>7-9</sup> Moreover, the annual costs of newer  
139 treatment options (such as biologics and small molecules) are often high.<sup>10,11</sup> Most  
140 importantly, even the latest treatments demonstrate efficiency in only a proportion of  
141 UC patients.<sup>12</sup> Therefore, the development of further medical treatment options, with  
142 favorable cost-benefit ratios and salutary side-effect profiles clearly represents an  
143 urgent requirement for UC management. In this respect, herbal and natural  
144 compound treatments constitute an appealing therapy option for UC patients.  
145 Secondly, many Swiss patients long for more natural therapies. In this context,  
146 several relevant studies report positive effect of curcuma<sup>13</sup> (*Curcuma zedoaria*, an  
147 Indian spice), or of boswellia tree resin (*Boswellia serrata*) as well as aloe vera<sup>14,15</sup> on  
148 UC patients.

149 In recent years there has been a rising interest in natural flavonoids, a subgroup  
150 of polyphenols, due to their beneficial effects on many conditions including  
151 cardiovascular disease and cancer. Anthocyanins (AC), compounds belonging to  
152 flavonoids, are abundant in red, blue and black berries, but also present in red wine  
153 and dark colored vegetables.<sup>16,17</sup>



154 AC have been associated with many protective biological effects, including  
155 antioxidative, anticarcinogenic, antimicrobial, and anti-inflammatory properties.<sup>15,18,19</sup>  
156 Due to their phenolic structure, AC exhibit anti-oxidative capacity *in vivo* as they  
157 scavenge reactive oxygen species (ROS),<sup>18,20</sup> a classical effect of 5-ASA.<sup>21</sup> AC interrupt  
158 pro-inflammatory signaling and are inhibitors of 5-lipoxygenase, a key enzyme  
159 implicated in the arachidonic acid pathway, for the biosynthesis of active  
160 leukotrienes (mainly via the unstable intermediate LTA<sub>4</sub> to LTB<sub>4</sub> and 5-HETE<sup>22,23</sup>). In  
161 the presence of flavonoids monocytes release less tumor necrosis factor (TNF) and  
162 interleukin (IL) – 8.<sup>24</sup> AC also impede activation of nuclear factor  $\kappa$ B (NF- $\kappa$ B) by  
163 inhibition of proteasomal function. NF- $\kappa$ B as well as TNF and IL-8 constitute key  
164 molecules orchestrating inflammation in IBD.<sup>15,25,26</sup>

165 Several research groups<sup>27-33</sup> including ours<sup>19,34-39</sup> reported a beneficial effect of  
166 AC on preclinical models of UC. In view of the aforementioned results, the potential  
167 of AC in a small uncontrolled pilot trial in 13 patients with UC was tested.<sup>40</sup> During  
168 six weeks, patients received a daily AC-rich extract from bilberries (*Vaccinium*  
169 *myrtillus*). Strikingly, clinical disease activity, as well endoscopic histological and  
170 biochemical indicators for intestinal inflammation markedly improved. Side effects  
171 were not observed. These data suggest AC as a potential adjunctive treatment option  
172 in UC with very few, if any, side effects.<sup>40,41</sup>

173 This study aims to confirm these results in a multi-center double-blind, placebo  
174 controlled, parallel group study to evaluate the efficacy, safety and tolerability of an  
175 anthocyanin rich extract (ACRE) in subjects with moderately active UC.

## 176 **Materials and Methods**

### 177 **Study Population**

178 Patients with moderately or severely active UC were recruited between April  
179 2019 and March 2021 at six IBD centers in Switzerland. Moderately or severely active  
180 UC was defined as a Mayo score 6-12 with an endoscopic sub-score  $\geq 2$ . Patients aged  
181 18–70 years and diagnosed with UC since at least three months with the disease  
182 extending at least 15 cm from the anal verge were included. Current oral or rectal 5-  
183 ASA/ sulfapyridine (SP) use or a history of oral or rectal 5-ASA/SP was allowed.  
184 Furthermore, patients were eligible for the study if they fulfilled one of the following  
185 criteria: a. Steroid intake up to 30 mg/day as well as a history of steroids dependency,  
186 refractory, or intolerance, including no steroids treatment due to earlier side-effects.  
187 OR b. Active disease despite induction therapy with 5-ASA agents, either  
188 mesalamine (2–4.8 g/day) or sulfasalazine (4–6 g/day) administered for at least two  
189 weeks. Topical treatment with 5-ASA was permissible but not sufficient for inclusion  
190 in the study. OR c. Intolerance to oral 5-ASA or azathioprine. OR d. Active disease  
191 despite thiopurine (adequately dosed according to treatment guidelines,<sup>42</sup> such as 2-3  
192 mg/kg for azathioprine) or methotrexate treatment administered for at least 12  
193 weeks. OR e. Active disease despite treatment with biologics effective in UC or  
194 calcineurin inhibitors. No restrictions regarding other IBD therapies applied:  
195 Azathioprine/6-mercaptopurine was allowed, providing that the dose had been  
196 stable for 8 weeks prior to baseline and had been initiated at least two months before  
197 screening. TNF inhibitors (i.e. infliximab, adalimumab or golimumab) were allowed,

198 providing that the dose was unchanged for at least two months prior to baseline and  
199 during the study treatment period. Vedolizumab and tofacitinib were allowed,  
200 providing that the dose remained unchanged for at least two months prior to  
201 baseline and during the study treatment period.

202 Exclusion criteria were a suspicion or diagnosis of Crohn's disease, ischemic  
203 colitis, radiation colitis, indeterminate colitis, infectious colitis, diverticular disease  
204 associated colitis, microscopic colitis, massive pseudopolyposis or a colonic stenosis  
205 that could not be passed endoscopically, acute severe UC (as defined by Truelove  
206 and Witt's criteria<sup>43</sup>) and/or signs of systemic toxicity, UC limited to the rectum  
207 (disease which extends <15 cm above the anal verge), long term treatment with  
208 antibiotics or non-steroidal anti-inflammatory drugs (NSAID) within two weeks  
209 prior to screening (one short treatment regime for antibiotics and occasional use of  
210 NSAID was allowed), and within at least 30 days after last treatment of the  
211 experimental product prior to enrolment history of malignancy, a history or presence  
212 of any clinically significant disorder that, in the opinion of the investigator, could  
213 impact on the patient's ability to adhere to the study protocol and study procedures  
214 or would confound the study result or compromise patient safety.

215 All patients signed an informed consent form. The study was approved by the  
216 ethics committee of each center (BASEC2017-00156) and was conducted in  
217 accordance with the latest revision of Declaration of Helsinki<sup>44</sup> as well as the  
218 guidelines of Good Clinical Practice.<sup>45</sup> Moreover, the study was registered in the US  
219 online database of clinical research studies [ClinicalTrials.gov](https://clinicaltrials.gov) (NCT04000139). All

220 authors were offered full access to the study data and reviewed and approved the  
221 final manuscript.

222

### 223 **Study design and procedures**

224 This was a multicenter randomized, double-blind, placebo-controlled trial.  
225 Patients with active moderate-severe UC despite state of the art 5-ASA, steroid,  
226 immunosuppressive or biological treatment were enrolled. Patients were  
227 randomized 2:1 (ACRE: placebo).

228 Upon study entry, all patients were instructed to continue their current  
229 medications unchanged. They either received a standardized anthocyanin extract  
230 (ACRE, referring to 800-1000 mg AC) administered *per os* three times daily or an  
231 optically identical placebo. Of note, similar or even lower AC doses have been  
232 previously administered in human studies investigating (extra)intestinal beneficial  
233 actions and with favorable results.<sup>40,46,47</sup> As the ACRE capsule preparation contained  
234 purple compounds (which could not be eliminated during the production process),  
235 we added equally purple powder to the placebo capsule preparation, in order to  
236 avoid any unblinding. The total duration of investigational product administration  
237 amounted to eight weeks (56 days). All participating physicians were blinded to  
238 treatment assignment throughout the study. After enrollment, patients underwent a  
239 physical examination and laboratory blood tests including a complete blood count,  
240 liver function tests, and C-reactive protein, which were performed at both baseline

241 and at the end of the phase protocol. Patients also underwent flexible  
242 rectosigmoidoscopy at study entry (baseline) and at week 8, and endoscopic activity  
243 was determined according to the endoscopic Mayo index sub-score<sup>48</sup> by a local and a  
244 central reader.

245

## 246 **Clinical Assessment and Trial End Points**

247 Primary objective of the study was to evaluate the efficacy of the ACRE  
248 preparation in subjects with moderately-severely active UC according to clinical,  
249 endoscopic, histologic and biochemical markers. Secondary objectives included the  
250 effects of ACRE on quality of life (QoL) as well as its safety.

251 (Mayo score 6-12, endoscopic sub-score  $\geq 2$ ) by comparing the clinical response  
252 rate of subjects on an ACRE versus a placebo arm at week 8. As clinical response was  
253 defined the reduction of total Mayo score (TMS)  $\geq 3$  points. Of note, the mentioned  
254 cut-off for clinical response exhibits an established validity in several studies  
255 previously.<sup>49-51</sup> Secondary objectives were the evaluation of 1) e ACRE-efficacy at  
256 week 8 where clinical remission is defined as Mayo Score  $\leq 2$ , with no individual sub-  
257 score  $> 1$ ; 2) ACRE safety and tolerability; 3) efficacy of an ACRE preparation in  
258 subjects with moderately active UC compared to placebo in clinical remission,  
259 clinical response and clinical symptoms; 4) ACRE efficacy in subjects with  
260 moderately-severe active UC compared to placebo in endoscopic and histological  
261 remission and response; 5) quality of life (QOL) in patients of ACRE arm.

262 The primary endpoint was the clinical response at week 8 with clinical response  
263 defined as a reduction of TMS by  $\geq 3$  points, similar to previous studies.<sup>49-51</sup>

264 Secondary endpoints were:

265 • The proportion of patients with symptomatic remission at week 8, defined by  
266 the presence of both, a Mayo rectal bleeding sub-score of 0, and a stool frequency  
267 subscore of 0 or 1 (with at least one point decrease from baseline, week 0), (patient  
268 reported outcome) [PRO2].<sup>52</sup>

269 • The proportion of patients without rectal bleeding at week 8, defined by a  
270 Mayo rectal sub-score bleeding of 0.

271 • The proportion of patients with normal or enhanced stool frequency at week  
272 8, defined by the Mayo stool frequency sub-score of 0 or 1 (with at least one point  
273 decrease from baseline, week 0).

274 Other secondary endpoints assessed rectal bleeding, clinical response and  
275 remission at week 4, durable remission (i.e. remission in weeks 8 and 12) and clinical  
276 response at week 8 according to the modified Mayo-score, defined as a three point  
277 and  $\geq 30\%$  drop from baseline of the sum of the rectal bleeding, stool frequency,  
278 endoscopy score (excluding friability) and physicians' global assessment (PGA).

279 • The proportion of patients with endoscopic remission at week 8, defined by a  
280 modified Mayo endoscopic sub-score<sup>48</sup> of 0 or 1 (excluding friability).

281 • The proportion of patients with histological remission at week 8, defined by a  
282 Geboes Index<sup>53</sup> of grade 0 or 1.

283           • Mean change in fecal calprotectin concentrations at weeks 1, 2, 4, and 8  
284 compared to baseline, week 0.

285           • Mean change in steroid dosage compared to baseline for patients in remission  
286 at week 8 to 12.

287           • Mean change in each of the short inflammatory bowel disease questionnaire  
288 (SIBDQ)<sup>54</sup> sub-domains at week 8 compared to baseline (week 0).

289 The rate and time point of premature study withdrawals between both arms was also  
290 explored in the data analysis.

291 Data acquisition and management were performed using OpenClinica  
292 Community Edition, Version 3.14, and an OpenClinica eCRF.

293

#### 294 **Analysis plan**

295 A sample size of 112 patients was initially planned, leading to 100 patients  
296 completing the study, assuming a drop-out rate of 12%, based on a frequentist power  
297 calculation. According to our previous data, a clinical response was assumed in the  
298 active treatment arm of 55% and in the placebo of 25%. For a 1:1 placebo vs. verum  
299 randomization ratio, a patient number of 41 per group would be sufficient to achieve  
300 statistical significance with a power of 80%, assuming an  $\alpha$ -error of maximal 5%. For  
301 the planned 1:2 ratio the respective numbers were be 33 (placebo) and 66 (verum)  
302 patients for both the groups. The analysis of the primary endpoint was conducted on  
303 the FAS (full analysis set) and PPS (per-protocol set). Data analysis was performed

304 using SAS version 9.4 (Windows x64 version). Missing singular data items were  
305 carried forward. This did not apply, of course, when entire visits were missed (p.ex.,  
306 in the case of premature study termination).

307

## 308 **RESULTS**

### 309 **Study Population**

310 Out of 48 patients screened in a total of six Swiss trial centers, 34 (70.9%) were  
311 enrolled and randomized, whereas 14 (29.1%; 4 females and 10 males) were  
312 considered screening failures.

313 Five randomized ACRE and two placebo patients prematurely terminated the  
314 study before the scheduled end of treatment at visit 3 (week 8). One ACRE patient  
315 started prednisone (20 mg/day) treatment at visit 1 and was excluded from all  
316 analyses for violation of the protocol. Thus, 18 ACRE and eight placebo patients  
317 could be analyzed in the per-protocol-set (PPS).

318 At screening, the majority of patients (69.2%) were on concomitant steroid  
319 medication. 16.7% in the bilberry group and 25% in the placebo group received anti-  
320 TNF treatment. Patient baseline characteristics are enclosed in Table 1.

321

### 322 **Efficacy Analysis**

323 Primary endpoint (Clinical Response at Week 8)



324 Clinical response at week 8 was achieved in nine out of 18 ACRE patients and  
325 three out of eight (3/8) placebo patients (Figure 1, Table 2). This corresponds to an  
326 odds ratio (OR) for response of 1.667 in favor of ACRE arm, with a 90% confidence  
327 interval (CI) between 0.399 – 6.963 and a one-sided  $p = 0.278$  in the logistic analysis  
328 and the primary endpoint was not met.

329 In a post-hoc analysis, mean reduction in partial Mayo score was  $2.61 \pm 2.79$  for  
330 ACRE arm and  $2.00 \pm 3.07$  for placebo arm (Figure 2, not significant). Assuming a  
331 normal distribution, the 90% CI of the change in TMS does not include the point 0  
332 (no change) for ACRE while this point is within the 90% CI for placebo arm.

333 An interesting finding of this study is the unusual high percentage of placebo  
334 response, i.e., 37.5% for the clinical response and 62.5% for the Mayo score  
335 amelioration.

336

### 337 Secondary endpoints

338 The secondary endpoint of clinical remission at week 8 was achieved in 9/18  
339 patients of ACRE arm versus 3/8 patients of placebo arm (CI 0.399–6.963;  $p=0.278$ , not  
340 significant), even though we noted numerical improvements in both individual sub-  
341 scores rectal bleeding and stool frequency (Table 3).

342

### 343 Endoscopic Remission at Week 8

344 The endoscopic findings (with central reading and site reading) yielded similar  
345 results, which are inconclusive and fail to demonstrate therapeutic effects.

346

#### 347 Change in fecal calprotectin Endpoint vs. Baseline

348 Fecal calprotectin remained practically the same in placebo group between  
349 baseline and end of experiment values ( $947 \pm 1039$  to  $1040 \pm 1179$ ) whereas it  
350 significantly decreased for ACRE group ( $1049 \pm 1139$  to  $557 \pm 756 \mu\text{g/g}$ ,  $p=0.035$ ). No  
351 difference for any of the other secondary endpoints was noted.

#### 352 Safety Analysis

353 Among the treated patients, a total of 68 adverse events, two of which were  
354 regarded to be serious, were recorded in 29 patients. All serious adverse events were  
355 assessed as unrelated to study medication. One patient developed an infectious  
356 colitis before enrolment. Another individual experienced an exacerbation of UC,  
357 which required hospitalization. Overall ACRE was very well tolerated and no new  
358 safety signals were detected.

359

## 360 **DISCUSSION**

361 In this multi-center, randomized, double-blind and placebo controlled, phase  
362 IIa study, we aimed to evaluate the efficacy, safety as well as tolerability of ACRE in  
363 patients with UC. Although the clinical response at the end of the study did not

364 differ between the two arms, a statistically significant difference was recorded in the  
365 secondary endpoint of fecal calprotectin.

366 Fecal calprotectin serves as a valuable indicator of inflammation within the  
367 intestines<sup>55,56</sup> and has become an integral component of routine testing for diagnosing  
368 and monitoring IBD. According to a recent meta-analysis, fecal calprotectin is an  
369 inexpensive, valuable and rather accurate predictor IBD relapses.<sup>55</sup> Additionally,  
370 further evidence has established fecal calprotectin as a useful marker recognizing an  
371 early response to IBD treatment, since it correlates robustly with serologic markers,  
372 endoscopic inflammation and disease activity indices of IBD subjects.<sup>56</sup>

373 As aforementioned, our research group firstly reported in 2013 within a pilot  
374 study<sup>40</sup> the beneficial effects of bilberries on UC patients, results that we could also  
375 confirm later on.<sup>35</sup> Comparable beneficial results of have been demonstrated  
376 independently by Kropat et al.<sup>57</sup> An ongoing relevant Australian clinical trial with  
377 double-blind, randomized, controlled, multi-arm design has been recently  
378 announced,<sup>58</sup> investigating the effect of administration of AC and/or multi-strain  
379 probiotics on UC patients.

380 In respect to the available *in vivo* preclinical scientific evidence, we reported as  
381 early as 2011 that bilberries and their AC positively impacted on an experimental  
382 acute and chronic colitis mouse model.<sup>19</sup> Later, and again by utilizing the same  
383 murine model mimicking human UC and UC-associated cancer, we demonstrated<sup>36</sup>  
384 that AC ingestion could avert the onset and progression of murine tumors in colon.

385 Comparable favorable results of AC on IBD murine models have been henceforth  
386 published by other study groups.<sup>29-31,59,60</sup>

387 Interestingly, there is emerging evidence, that AC administration offers  
388 beneficial effects beyond IBD to further intestinal diseases such as colorectal  
389 carcinoma and irritable bowel syndrome.<sup>61</sup> Bilberries and/or AC have also been  
390 investigated as a treatment targeting extraintestinal organs in various settings and  
391 have shown a positive impact in clinical trials, among others, for vascular health and  
392 cognitive function,<sup>46</sup> or metabolic syndrome and associated conditions.<sup>26</sup> A very  
393 recent US study with a large sample of patients (n = 37,232) found a direct inverse  
394 relationship between overall mortality risk and consumption of diverse berries and  
395 their containing flavonoids.<sup>17</sup>

396 One of the reasons for the health-promoting effects of AC is regarded to be their  
397 antioxidant effect owing to their phenolic structure, enabling them to neutralize  
398 ROS.<sup>39</sup> Additionally, AC display antimicrobial effects, such as against *Bacillus cereus*,  
399 and *Helicobacter pylori*.<sup>62</sup> They also reduce the expression of various genes involved in  
400 atherosclerosis formation in animal models.<sup>63</sup> Moreover, AC inhibit inflammation-  
401 promoting pathways in immune cells.<sup>39</sup>

402 As stressed in the results section, an unusual high percentage of placebo  
403 response for the Mayo score improvement was noted. In this respect, a Cochrane  
404 meta-analysis<sup>64</sup> of 61 studies estimated the placebo response and remission rates of  
405 induction treatment for UC (adult population) to be 33% and 12%, respectively.  
406 Placebo effect and rates of remission fluctuated based on several factors, including

407 the severity of endoscopic disease and the rectal bleeding score upon trial initiation,  
408 the type of medication used, duration of the disease, and the specific time when the  
409 primary outcome was assessed.<sup>64</sup>

410 In a second more recent systematic review with meta-analysis (2022), clinical,  
411 endoscopic, histological and safety placebo rates in induction and maintenance trials  
412 of UC have been evaluated.<sup>65</sup> After considering a total number of 119 trials (of which  
413 92 in induction and 27 in maintenance) the abovementioned parameters were for the  
414 induction studies 11%, 19% and 15%, respectively. Again, the authors deduced  
415 placebo response rates observed in trials for UC differ depended on the endpoint  
416 evaluated, whether it pertains to response assessment or achieving remission, and  
417 whether the trial focuses on induction or maintenance.

418 The purple color of the drug as well as the placebo might be partially  
419 responsible for the high placebo rates. As a possible interpretation of this unexpected  
420 placebo effect, studies conducted in the past have identified the color of the placebo  
421 pills to correlate with outcomes.<sup>66-68</sup> Thus, the colors of drugs may impact how their  
422 effects are perceived and may also play a role in their effectiveness. Additionally,  
423 there appears to be a connection between the coloring of drugs that affect the central  
424 nervous system and the conditions they are prescribed for. In this context there is  
425 evidence that red, yellow, and orange color of pills are linked to a stimulant effect,  
426 whereas blue, purple and green are connected to a tranquillizing – sedative effect.<sup>66-68</sup>

427 The strengths of this study includes the double-blinded, randomized and multi-  
428 center study design. The low number of participants is the main limitation of this

429 study, this is at least partially due to restriction during the COVID-19 pandemic.  
430 since individual patients, as aforementioned commented, have impacted relevantly  
431 the outcome. However, this did not prevent a statistical significance for fecal  
432 calprotectin between the two study arms.

433

#### 434 **CONCLUSION**

435 In conclusion, ACRE did not induce clinical response at 8 weeks in patients  
436 with moderate to severe UC. However, due to limitations to recruit a large sample  
437 size, limiting some analyses, significant decreases in fecal calprotectin levels upon  
438 ACRE treatment were noted.

439

#### 440 **CONFLICTS OF INTEREST**

441 PS received consulting fees from Pfizer, Abbvie, Takeda and Janssen-Cilag and travel  
442 support from Falk, UCB and Pfizer.

443 LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap,  
444 Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma.

445 GR declares consulting fees from Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene,  
446 FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche,  
447 UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; speaker's honoraria from Astra  
448 Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller;  
449 and grants support from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD,  
450 Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller.

451 BM reports traveling fees from Takeda, Vifor, Gilead and MSD. BM received fees as a  
452 speaker from Takeda. BM has served at an advisory board for Abbvie, Gilead,  
453 Takeda and BMS. BM has received research grants from MSD, BMS and Nestlé  
454 unrelated to the submitted work.

455 MD reports traveling fees from Takeda, FALK, Abbvie as well as consulting fees  
456 from Takeda.

457 Rest of the authors declare no compelling conflict of interests.

#### 458 **ACKNOWLEDGEMENTS**

459 The authors wish to thank all the patients for their cooperation as well as their  
460 families for their support during this endeavor.

461

#### 462 **REFERENCES**

- 463 1. Lang BM, Ledergerber M, Jordi SBU, et al. Because I'm happy - positive affect and its  
464 predictive value for future disease activity in patients with inflammatory bowel  
465 diseases: a retrospective cohort study. *Therap Adv Gastroenterol.*  
466 2023;16:17562848231179335.
- 467 2. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis.  
468 *Lancet.* 2017;389(10080):1756-1770.
- 469 3. Norouzkhani N, Faramarzi M, Ghodousi Moghadam S, et al. Identification of the  
470 informational and supportive needs of patients diagnosed with inflammatory bowel  
471 disease: a scoping review. *Front Psychol.* 2023;14:1055449.
- 472 4. Awadhi SA, Alborai M, Albaba EA, et al. Treatment of Patients with Mild to Moderate  
473 Ulcerative Colitis: A Middle East Expert Consensus. *J Clin Med.* 2023;12(21).
- 474 5. Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based  
475 Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current  
476 Management. *J Crohns Colitis.* 2017;11(7):769-784.
- 477 6. Dai N, Haidar O, Askari A, Segal JP. Colectomy rates in ulcerative colitis: A  
478 systematic review and meta-analysis. *Dig Liver Dis.* 2023;55(1):13-20.
- 479 7. Wang K, Zhu Y, Liu K, Zhu H, Ouyang M. Adverse events of biologic or small  
480 molecule therapies in clinical trials for inflammatory bowel disease: A systematic  
481 review and meta-analysis. *Heliyon.* 2024;10(4):e25357.
- 482 8. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD.  
483 *Best Pract Res Clin Gastroenterol.* 2010;24(2):167-182.

- 484 9. Larussa T, Basile A, Palleria C, et al. Real-life burden of adverse reactions to  
485 biological therapy in inflammatory bowel disease: a single-centre prospective case  
486 series. *Med Pharm Rep.* 2021;94(3):289-297.
- 487 10. Alulis S, Vadstrup K, Olsen J, et al. The cost burden of Crohn's disease and  
488 ulcerative colitis depending on biologic treatment status - a Danish register-based  
489 study. *BMC Health Serv Res.* 2021;21(1):836.
- 490 11. van Linschoten RCA, Visser E, Niehot CD, et al. Systematic review: societal cost of  
491 illness of inflammatory bowel disease is increasing due to biologics and varies  
492 between continents. *Aliment Pharmacol Ther.* 2021;54(3):234-248.
- 493 12. Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics  
494 and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a  
495 systematic review and network meta-analysis. *Lancet Gastroenterol Hepatol.*  
496 2022;7(2):161-170.
- 497 13. Pituch-Zdanowska A, Dembinski L, Banaszkiwicz A. Old but Fancy: Curcumin in  
498 Ulcerative Colitis-Current Overview. *Nutrients.* 2022;14(24).
- 499 14. Gupta M, Mishra V, Gulati M, et al. Natural compounds as safe therapeutic options  
500 for ulcerative colitis. *Inflammopharmacology.* 2022;30(2):397-434.
- 501 15. Triantafyllidi A, Xanthos T, Papalois A, Triantafyllidis JK. Herbal and plant therapy in  
502 patients with inflammatory bowel disease. *Ann Gastroenterol.* 2015;28(2):210-220.
- 503 16. Lang Y, Gao N, Zang Z, et al. Classification and antioxidant assays of polyphenols: a  
504 review. *Journal of Future Foods.* 2024;4(3):193-204.
- 505 17. Zhang L, Muscat JE, Chinchilli VM, Kris-Etherton PM, Al-Shaar L, Richie JP.  
506 Consumption of Berries and Flavonoids in Relation to Mortality in NHANES, 1999-  
507 2014. *J Nutr.* 2024;154(2):734-743.
- 508 18. Krga I, Milenkovic D. Anthocyanins: From Sources and Bioavailability to  
509 Cardiovascular-Health Benefits and Molecular Mechanisms of Action. *J Agric Food*  
510 *Chem.* 2019;67(7):1771-1783.
- 511 19. Piberger H, Oehme A, Hofmann C, et al. Bilberries and their anthocyanins ameliorate  
512 experimental colitis. *Mol Nutr Food Res.* 2011;55(11):1724-1729.
- 513 20. Tena N, Martin J, Asuero AG. State of the Art of Anthocyanins: Antioxidant Activity,  
514 Sources, Bioavailability, and Therapeutic Effect in Human Health. *Antioxidants*  
515 *(Basel).* 2020;9(5).
- 516 21. Ahnfelt-Ronne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical  
517 evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.  
518 *Gastroenterology.* 1990;98(5 Pt 1):1162-1169.
- 519 22. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I. Inhibition of 5-lipoxygenase  
520 pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-  
521 aminosalicylic acid. *Dig Dis Sci.* 1987;32(6):577-582.
- 522 23. Allgayer H, Stenson WF. A comparison of effects of sulfasalazine and its metabolites  
523 on the metabolism of endogenous vs. exogenous arachidonic acid.  
524 *Immunopharmacology.* 1988;15(1):39-46.
- 525 24. Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al-Mssallem MQ.  
526 Flavonoids as Potential Anti-Inflammatory Molecules: A Review. *Molecules.*  
527 2022;27(9).
- 528 25. Sahoo DK, Heilmann RM, Paital B, et al. Oxidative stress, hormones, and effects of  
529 natural antioxidants on intestinal inflammation in inflammatory bowel disease. *Front*  
530 *Endocrinol (Lausanne).* 2023;14:1217165.
- 531 26. Sharma A, Lee HJ. Anti-Inflammatory Activity of Bilberry (*Vaccinium myrtillus* L.). *Curr*  
532 *Issues Mol Biol.* 2022;44(10):4570-4583.
- 533 27. Akiyama S, Nesumi A, Maeda-Yamamoto M, Uehara M, Murakami A. Effects of  
534 anthocyanin-rich tea "Sunrouge" on dextran sodium sulfate-induced colitis in mice.  
535 *Biofactors.* 2012;38(3):226-233.
- 536 28. Li L, Wang L, Wu Z, et al. Anthocyanin-rich fractions from red raspberries attenuate  
537 inflammation in both RAW264.7 macrophages and a mouse model of colitis. *Sci Rep.*  
538 2014;4:6234.




- 539 29. Zhao L, Zhang Y, Liu G, Hao S, Wang C, Wang Y. Black rice anthocyanin-rich extract  
540 and rosmarinic acid, alone and in combination, protect against DSS-induced colitis in  
541 mice. *Food Funct.* 2018;9(5):2796-2808.
- 542 30. Peng Y, Yan Y, Wan P, et al. Gut microbiota modulation and anti-inflammatory  
543 properties of anthocyanins from the fruits of *Lycium ruthenicum* Murray in dextran  
544 sodium sulfate-induced colitis in mice. *Free Radic Biol Med.* 2019;136:96-108.
- 545 31. Li S, Wang T, Wu B, et al. Anthocyanin-containing purple potatoes ameliorate DSS-  
546 induced colitis in mice. *J Nutr Biochem.* 2021;93:108616.
- 547 32. Mu J, Xu J, Wang L, Chen C, Chen P. Anti-inflammatory effects of purple sweet  
548 potato anthocyanin extract in DSS-induced colitis: modulation of commensal bacteria  
549 and attenuated bacterial intestinal infection. *Food Funct.* 2021;12(22):11503-11514.
- 550 33. Zhang G, Gu Y, Dai X. Protective Effect of Bilberry Anthocyanin Extracts on Dextran  
551 Sulfate Sodium-Induced Intestinal Damage in *Drosophila melanogaster*. *Nutrients.*  
552 2022;14(14).
- 553 34. Roth S, Spalinger MR, Muller I, Lang S, Rogler G, Scharl M. Bilberry-derived  
554 anthocyanins prevent IFN-gamma-induced pro-inflammatory signalling and cytokine  
555 secretion in human THP-1 monocytic cells. *Digestion.* 2014;90(3):179-189.
- 556 35. Roth S, Spalinger MR, Gottier C, et al. Bilberry-Derived Anthocyanins Modulate  
557 Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. *PLoS One.*  
558 2016;11(5):e0154817.
- 559 36. Lippert E, Ruemmele P, Obermeier F, et al. Anthocyanins Prevent Colorectal Cancer  
560 Development in a Mouse Model. *Digestion.* 2017;95(4):275-280.
- 561 37. Dreiseitel A, Schreier P, Oehme A, et al. Anthocyanins and anthocyanidins are poor  
562 inhibitors of CYP2D6. *Methods Find Exp Clin Pharmacol.* 2009;31(1):3-9.
- 563 38. Dreiseitel A, Schreier P, Oehme A, et al. Inhibition of proteasome activity by  
564 anthocyanins and anthocyanidins. *Biochem Biophys Res Commun.* 2008;372(1):57-  
565 61.
- 566 39. Scharl M, Rogler G, Biedermann L. Anthocyane, Heidelbeeren und Curcuma:  
567 Wirksame Therapeutika bei Darmentzündungen? *Schweizerische Zeitschrift für*  
568 *Ganzheitsmedizin / Swiss Journal of Integrative Medicine.* 2017;29(3):137-140.
- 569 40. Biedermann L, Mwinyi J, Scharl M, et al. Bilberry ingestion improves disease activity  
570 in mild to moderate ulcerative colitis - an open pilot study. *J Crohns Colitis.*  
571 2013;7(4):271-279.
- 572 41. Li S, Wu B, Fu W, Reddivari L. The Anti-inflammatory Effects of Dietary Anthocyanins  
573 against Ulcerative Colitis. *Int J Mol Sci.* 2019;20(10).
- 574 42. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical  
575 Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol.* 2019;114(3):384-413.
- 576 43. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial.  
577 *Br Med J.* 1955;2(4947):1041-1048.
- 578 44. World Medical A. World Medical Association Declaration of Helsinki: ethical principles  
579 for medical research involving human subjects. *JAMA.* 2013;310(20):2191-2194.
- 580 45. (R3) IE. Guideline on good clinical practice (GCP) Step 2b. 2023;  
581 <https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice-scientific-guideline>.  
582 Accessed 15.03.2024.
- 583 46. Wood E, Hein S, Mesnage R, et al. Wild blueberry (poly)phenols can improve  
584 vascular function and cognitive performance in healthy older individuals: a double-  
585 blind randomized controlled trial. *Am J Clin Nutr.* 2023;117(6):1306-1319.
- 586 47. Zhang H, Xu Z, Zhao H, et al. Anthocyanin supplementation improves anti-oxidative  
587 and anti-inflammatory capacity in a dose-response manner in subjects with  
588 dyslipidemia. *Redox Biol.* 2020;32:101474.
- 589 48. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy  
590 for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med.*  
591 1987;317(26):1625-1629.
- 592 49. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the  
593 noninvasive components of the Mayo score to assess clinical response in ulcerative  
594 colitis. *Inflamm Bowel Dis.* 2008;14(12):1660-1666.

- 595 50. Sandborn WJ, Sands BE, Vermeire S, et al. Modified Mayo score versus Mayo score  
596 for evaluation of treatment efficacy in patients with ulcerative colitis: data from the  
597 tofacitinib OCTAVE program. *Therap Adv Gastroenterol*.  
598 2022;15:17562848221136331.
- 599 51. Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and Safety of Abruilumab in a  
600 Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.  
601 *Gastroenterology*. 2019;156(4):946-957 e918.
- 602 52. Bewtra M, Brensinger CM, Tomov VT, et al. An optimized patient-reported ulcerative  
603 colitis disease activity measure derived from the Mayo score and the simple clinical  
604 colitis activity index. *Inflamm Bowel Dis*. 2014;20(6):1070-1078.
- 605 53. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Lofberg R. A reproducible grading  
606 scale for histological assessment of inflammation in ulcerative colitis. *Gut*.  
607 2000;47(3):404-409.
- 608 54. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease  
609 Questionnaire: a quality of life instrument for community physicians managing  
610 inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse  
611 Prevention Trial. *Am J Gastroenterol*. 1996;91(8):1571-1578.
- 612 55. Shi JT, Chen N, Xu J, et al. Diagnostic Accuracy of Fecal Calprotectin for Predicting  
613 Relapse in Inflammatory Bowel Disease: A Meta-Analysis. *J Clin Med*. 2023;12(3).
- 614 56. Lee YW, Lee KM, Lee JM, et al. The usefulness of fecal calprotectin in assessing  
615 inflammatory bowel disease activity. *Korean J Intern Med*. 2019;34(1):72-80.
- 616 57. Kropat C, Mueller D, Boettler U, et al. Modulation of Nrf2-dependent gene  
617 transcription by bilberry anthocyanins in vivo. *Mol Nutr Food Res*. 2013;57(3):545-  
618 550.
- 619 58. Cosier D, Lambert K, Batterham M, Sanderson-Smith M, Mansfield KJ, Charlton K.  
620 The INHABIT (synergistic effect of anthocyanin and probiotics in) Inflammatory  
621 Bowel Disease trial: a study protocol for a double-blind, randomised, controlled, multi-  
622 arm trial. *J Nutr Sci*. 2024;13:e1.
- 623 59. Chen J, Jiang F, Xu N, et al. Anthocyanin Extracted from Purple Sweet Potato  
624 Alleviates Dextran Sulfate Sodium-Induced Colitis in Mice by Suppressing Pyroptosis  
625 and Altering Intestinal Flora Structure. *J Med Food*. 2024;27(2):110-122.
- 626 60. Mo J, Ni J, Zhang M, et al. Mulberry Anthocyanins Ameliorate DSS-Induced  
627 Ulcerative Colitis by Improving Intestinal Barrier Function and Modulating Gut  
628 Microbiota. *Antioxidants (Basel)*. 2022;11(9).
- 629 61. Liu Y, Fernandes I, Mateus N, Oliveira H, Han F. The Role of Anthocyanins in  
630 Alleviating Intestinal Diseases: A Mini Review. *J Agric Food Chem*. 2024.
- 631 62. Nohynek LJ, Alakomi HL, Kahkonen MP, et al. Berry phenolics: antimicrobial  
632 properties and mechanisms of action against severe human pathogens. *Nutr Cancer*.  
633 2006;54(1):18-32.
- 634 63. Mauray A, Felgines C, Morand C, Mazur A, Scalbert A, Milenkovic D. Bilberry  
635 anthocyanin-rich extract alters expression of genes related to atherosclerosis  
636 development in aorta of apo E-deficient mice. *Nutr Metab Cardiovasc Dis*.  
637 2012;22(1):72-80.
- 638 64. Jairath V, Zou GY, Parker CE, et al. Placebo response and remission rates in  
639 randomised trials of induction and maintenance therapy for ulcerative colitis.  
640 *Cochrane Database Syst Rev*. 2017;9(9):CD011572.
- 641 65. Sedano R, Hogan M, Nguyen TM, et al. Systematic Review and Meta-Analysis:  
642 Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and  
643 Maintenance Trials of Ulcerative Colitis. *J Crohns Colitis*. 2022;16(2):224-243.
- 644 66. Bhugra D, Ventriglio A, Till A, Malhi G. Colour, culture and placebo response. *Int J*  
645 *Soc Psychiatry*. 2015;61(6):615-617.
- 646 67. de Craen AJ, Roos PJ, de Vries AL, Kleijnen J. Effect of colour of drugs: systematic  
647 review of perceived effect of drugs and of their effectiveness. *BMJ*.  
648 1996;313(7072):1624-1626.
- 649 68. Jacobs KW, Nordan FM. Classification of placebo drugs: effect of color. *Percept Mot*  
650 *Skills*. 1979;49(2):367-372.

651

652

653




654

655

656


657

**Figure 1:** Clinical Response of both arms (ACRE vs placebo) at Week 8 after baseline. ACRE, Anthocyanin rich extract. Numbers within the bars indicate the absolute number of patients.



658

659 **Figure 2:** post-hoc analysis, mean reduction in partial Mayo score, with 90%  
660 confidence interval for mean, albeit without statistical significance. ACRE,  
661 anthocyanin rich extract.



662

663 **Figure 3:** Calprotectin levels ( $\mu\text{g/g}$ ) over the observation period between two arms.

664 ACRE, anthocyanin rich extract.

665

666 **Table 1: Baseline characteristics**

	<i>ACRE</i>	<i>Placebo</i>	<i>All patients</i>
Gender (f/m)	10/14	5/5	15/19
All randomized patients			
Gender (f/m)	8/10	4/4	12/14
Per protocol set			
Total Mayo Score (Mean value $\pm$ SD) at Screening	8.43 $\pm$ 1.31	8.50 $\pm$ 1.90	
Steroids/no steroids	14 (77.8%)	4 (50.0%)	18 (69.2%)
	4 (22.2%)	4 (50.0%)	8 (30.8%)
TNF tx/no TNF tx	3 (16.7%)	2 (25.0%)	5 (19.2%)
	15 (83.3%)	6 (75.0%)	21 (80.8%)

667 ACRE, anthocyanin rich extract; f/m, female/male; SD, standard deviation; TNF,

---

	<i>Treatment</i>	<i>p-value</i>
--	------------------	----------------

---

668 tumor necrosis factor; tx, treatment

669

670 **Table 2: Categorized Change in Total Mayo Score**

---

<i>Change in Total Mayo Score</i>	<i>Treatment</i>			
	<b>ACRE</b>		<b>Placebo</b>	
	Patients	%	Patients	%
Clinical response	9	50.0%	3	37.5
Improved	5	27.8%	2	25.0
Unchanged	2	11.1%	2	25.0
Worsened	2	11.1%	1	12.5
All	18	100.0%	8	100.0

---

671 ACRE, anthocyanin rich extract

672

673

674

675

676

677

678

679

680

681

682

683

684

---

	<b>ACRE</b>		<b>Placebo</b>		
	Patients	%	Patients	%	
Symptomatic remission	8/18	44.4	3/8	37.5	0.371
No bleeding	13/18	72.2	4/8	50.0	0.139
Normal stool frequency	10/18	11.1	4/8	50.0	0.397
Endoscopic remission	4/18	22.2	2/8	25	0.412

---

685 **Table 3: Categorized Changes at week 8**

686 ACRE, anthocyanin rich extract

687

688

689

690

691

692